Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$8.01 - $12.84 $26,433 - $42,372
-3,300 Closed
0 $0
Q3 2021

Nov 04, 2021

BUY
$11.94 - $16.09 $39,402 - $53,097
3,300 New
3,300 $42,000
Q4 2019

Feb 14, 2020

SELL
$9.73 - $19.31 $23,079 - $45,803
-2,372 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$10.15 - $16.89 $1.19 Million - $1.98 Million
-117,145 Reduced 98.02%
2,372 $24,000
Q2 2019

Aug 14, 2019

BUY
$14.6 - $20.6 $760,952 - $1.07 Million
52,120 Added 77.33%
119,517 $1.86 Million
Q1 2019

May 15, 2019

BUY
$15.53 - $19.75 $305,894 - $389,015
19,697 Added 41.29%
67,397 $1.23 Million
Q4 2018

Feb 14, 2019

BUY
$15.58 - $28.41 $440,508 - $803,264
28,274 Added 145.55%
47,700 $794,000
Q3 2018

Dec 21, 2021

BUY
$25.99 - $30.6 $60,166 - $70,839
2,315 Added 13.53%
19,426 $548,000
Q3 2018

Nov 14, 2018

BUY
$25.99 - $30.6 $366,069 - $431,001
14,085 Added 465.47%
17,111 $482,000
Q2 2018

Apr 21, 2020

BUY
$27.78 - $38.53 $39,003 - $54,096
1,404 Added 86.56%
3,026 $86,000
Q2 2018

Aug 14, 2018

SELL
$27.78 - $38.53 $388,669 - $539,073
-13,991 Reduced 89.61%
1,622 $45,000
Q1 2018

Oct 18, 2019

BUY
$27.78 - $35.19 $33,419 - $42,333
1,203 Added 8.35%
15,613 $491,000
Q1 2018

May 15, 2018

BUY
$27.78 - $35.19 $372,640 - $472,038
13,414 Added 1346.79%
14,410 $453,000
Q4 2017

Feb 14, 2018

SELL
$23.33 - $35.01 $1.61 Million - $2.42 Million
-69,204 Reduced 98.58%
996 $29,000
Q3 2017

Nov 14, 2017

BUY
$21.65 - $32.18 $1.52 Million - $2.26 Million
70,200
70,200 $2 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.